...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British journal of neurosurgery >Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
【24h】

Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.

机译：在新诊断的多形性胶质母细胞瘤中，伴有替莫唑胺与放疗并辅以替莫唑胺的令人鼓舞的经验：单机构经验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The purpose of this study was to report our experience with concomitant and adjuvant temozolomide (TMZ) with radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM). Forty-two newly diagnosed histopathologically proven patients with GBM underwent maximal safe resection followed by external radiotherapy to a total dose of 60 Gy in 30 fractions over 6 weeks along with concomitant oral TMZ (75 mg/m2) daily followed by adjuvant TMZ for 5 days every 28 days for six cycles (150 mg/m2 for the first cycle and 200 mg/m2 for rest of the cycles). Patients were monitored clinicoradiologically as per standard practice. Patients were 13-69 years of age with a median age of 49.5 years (31 males, 11 females). Fifty per cent of patients underwent a gross total resection of tumour, 43% had partial resection, and 7% an open or stereotactic biopsy only. 53% of the patients had a post-operative Karnofsky Performance Score (KPS) of 60-80%. All patients received concomitant radiation and TMZ with 74% of the patients completing six cycles of adjuvant TMZ. At a median follow-up of 12.5 months, the 1- and 2-year survival was 67 and 29%, respectively. The median overall and progression-free survival was 16.4 and 14.9 months respectively. Patients with pretreatment KPS of >80% had significantly better overall survival as compared with those having KPS
机译：这项研究的目的是报告在新诊断的多形性胶质母细胞瘤（GBM）患者中，伴有替莫唑胺（TMZ）联合放疗的经验。新近经组织病理学证实的42例GBM患者接受了最大程度的安全切除，然后在6周内接受30倍总剂量的60 Gy外部放射治疗，并伴有口服TMZ（75 mg / m2）每天口服，然后进行TMZ辅助治疗5天每28天进行六个周期（第一个周期为150 mg / m2，其余周期为200 mg / m2）。按照标准做法对患者进行临床放射学监测。患者年龄为13-69岁，中位年龄为49.5岁（男性31例，女性11例）。 50％的患者接受了肿瘤的完全切除，43％的患者接受了部分切除，7％的患者仅接受了开放或立体定向活检。 53％的患者术后卡诺夫斯基绩效评分（KPS）为60-80％。所有患者均接受了放疗和TMZ治疗，其中74％的患者完成了六个周期的TMZ辅助治疗。中位随访12.5个月，其1年和2年生存率分别为67％和29％。中位总体生存期和无进展生存期分别为16.4和14.9个月。与KPS <或= 80％的患者相比，KPS≥80％的患者的总生存期显着更好（中位生存期22.12 vs. 11.97个月; p = 0.026）。在治疗期间，通常分别有9％的3级贫血患者，2％的3级白带病患者和7％的3级或4级血小板减少症患者对治疗耐受良好。在最后一次随访中，在幸存的患者中，有30％的KPS维持率大于90％。放疗和TMZ联合佐剂TMZ可以延长多形性胶质母细胞瘤患者的生存期，并且在我们的患者人群中耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号